CGT Catapult annual review highlights the role of advanced therapies in supporting Government ambitions for public health

London, UK, 4 November 2025: Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, reveals the sector’s crucial contribution to the UK Government’s ambition of becoming one of the world’s top three life sciences economies by 2035.

In its latest annual review, the CGT Catapult demonstrates how it is uniquely positioned to deliver critical advances in the cell and gene therapy industry, from driving forward the industry’s productivity for the economy, to improving patient outcomes. In the last financial year, the organisation worked with 70 companies on advanced therapies innovation, 60% of which were SMEs based in the UK. The companies the CGT Catapult worked with raised over £177 million over the previous year.

For patients, access to potentially life-saving therapies continues to increase. As of April, there were a total of 17 therapies approved and reimbursed for use and, in 2024, 9.5% of global advanced therapy clinical trials had representation in the UK. Nine of the companies that the CGT Catapult worked with in the previous financial year were conducting clinical trials in the UK.

Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, said:

Many thanks to our collaborators in industry, healthcare and Government who we have worked with over the past year. Working together, we have delivered partnerships that supported industry growth, and helped ensure the UK maintains its position as a global leader in advanced therapies. The advanced therapies sector, is crucial to driving forward the Government’s mission of sustainable economic growth and improved health.